drugset / Trial / NCT02487498
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining an acceptable safety profile.
Timeline
- Start
- 2015-07-27
- Primary completion
- 2016-09-06
- Completion
- 2016-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glycopyrrolate | Small molecule | 15.6 ug | Inhaled |
| Subject | Indacaterol | Other / unclassified | 27.5 ug | Inhaled |
| Subject | Umeclidinium | Other / unclassified | 62.5 ug | Inhaled |
| Subject | Vilanterol | Other / unclassified | 25 ug | Inhaled |